IP Library Granted Patent US 8,362,235
Granted Patent B2
US 8,362,235 · App. 12/695,861 · Granted Jan 29, 2013

Carboxamide compounds and methods for using the same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,362,235
App. No.
12/695,861
Granted
Jan 29, 2013
Kind
B2
Abstract

Disclosed are carboxamide compounds as well as pharmaceutical compositions and methods of use. One embodiment is a compound having the structure in which R 1 , R 2 , R 3 , R 4 , T, p, q, w and x are as described herein. In certain embodiments, a compound disclosed herein activates the AMPK pathway, and can be used to treat metabolism-related disorders and conditions.

Claims (56)

1. A compound having the structural formula

or a pharmaceutically acceptable salt, or N-oxide thereof, wherein

R 1 is H, —(C 1 -C 4 alkyl), —C(O)—(C 1 -C 4 alkyl) or —C(O)O—(C 1 -C 4 alkyl);

each R 3 is independently selected from —(C 1 -C 3 alkyl), —(C 1 -C 3 haloalkyl), -halogen, —NO 2 and —CN;

w is 0, 1 or 2;

each R 4 is independently selected from —(C 1 -C 3 alkyl), —(C 1 -C 3 haloalkyl), -halogen, and two R 4 on the same carbon optionally combine to form oxo;

x is 0, 1 or 2;

Q and G are each independently a bond, —CH 2 —, —C(H)(R 16 )—, —C(R 16 ) 2 —, —S(O) 2 —;

v is 0, 1 or 2;

each R 15 is independently selected from —(C 1 -C 3 alkyl), —(C 1 -C 3 haloalkyl), -halogen, and two R 15 on the same carbon optionally combine to form oxo;

R 17 is phenyl or pyridyl, each optionally substituted with 1, 2 or 3 substituents selected from —(C 1 -C 3 alkyl), —(C 1 -C 3 haloalkyl), -halogen, —NO 2 and —CN,

R 5 is selected from —(C 1 -C 3 alkyl), —(C 1 -C 3 haloalkyl), -halogen, —NO 2 and —CN;

in which

each R 16 is independently selected from —(C 1 -C 3 alkyl), and optionally two of R 16 on the same carbon combine to form oxo.

2. A compound according to claim 1 , having the structural formula

3. A compound according to claim 1 , having the structural formula

4. A compound according to claim 1 , having the structural formula

in which one of X 1 , X 2 , X 3 and X 4 is N, and the others are carbons.

5. A compound according to claim 1 , wherein Q is —CH 2 —, a single bond, —C(O)—, —S(O) 2 — or —CH(CH 3 )—.

6. A compound according to claim 1 , wherein R 5 is chloro, fluoro, cyano, trifluoromethyl or NO 2 .

7. A compound according to claim 1 , wherein R 1 is H.

8. A compound according to claim 1 , wherein w is 0.

9. A compound according to claim 1 , wherein w is at least 1, and at least one R 3 is selected from the group consisting of halo, cyano, —(C 1 -C 3 fluoroalkyl) and NO 2 .

10. A compound according to claim 1 , wherein x is 0.

11. A compound according to claim 1 , wherein two R 4 groups combine to form an oxo.

12. A compound according to claim 1 , having the structural formula

13. A compound according to claim 1 , having the structural formula

in which R 25 is selected from halo, cyano, —(C 1 -C 3 fluoroalkyl), and NO 2 .

14. A compound according to claim 1 , wherein the compound is 5-(4-(4-cyanobenzyl)piperazine-1-carbonyl)-N-(1-(4-cyanobenzyl)piperidin-4-yl)picolinamide;

N-(1-(4-cyanobenzyl)piperidin-4-yl)-5-(4-(4fluorobenzyl)piperazine-1-carbonyl)picolinamide;

N-(1-(4-cyanobenzyl)piperidin-4-yl)-5-(4-(4-(trifluoromethyl)benzyl)piperazine-1-carbonyl)picolinamide

(S)-5-(4-(4-chlorophenyl)piperazine-1-carbonyl)-N-(1-(4-fluorobenzyl)pyrrolidin-3-yl)picolinamide;

(S)-5-(4-(4-chlorophenyl)piperazine-1-carbonyl)-N-(1-(pyridin-4-ylmethyl)pyrrolidin-3-yl)picolinamide;

(S)-5-(4-(4-chlorophenyl)piperazine-1-carbonyl)-N-(1-(4-cyanobenzyl)pyrrolidin-3-yl)picolinamide;

N-(1-(4-chlorobenzyl)pyrrolidin-3-yl)-5-(4-(4-chlorophenyl)piperazine-1-carbonyl)picolinamide; or 5-(4-(4-chlorophenyl)piperazine-1-carbonyl)-N-(1-(4-(trifluoromethyl)benzyl)pyrrolidin-3-yl)picolinamide.

15. A pharmaceutical composition comprising:

at least one pharmaceutically acceptable carrier, diluent or excipient; and

a compound according to claim 1 or a pharmaceutically acceptable salt or N-oxide thereof.

16. A method for activating the AMPK pathway in a cell, the method comprising

contacting the cell with an effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt or N-oxide thereof.

17. A compound according to claim 1 , in which v is 0, w is 0 and x is 0.

18. A compound according to claim 1 , wherein Q is —CH 2 —; a single bond; —S(O) 2 —; —C(O)—; or —CH(CH 3 )—.

19. A compound according to claim 1 , wherein R 5 is —Cl, —F, cyano, trifluoromethyl or difluoromethyl.

20. A compound according to claim 1 , wherein the R 17 phenyl or pyridyl is optionally substituted with one or two substituents selected from halo, cyano, —(C 1 -C 3 fluoroalkyl), and NO 2 .

21. A compound according to claim 1 , wherein G is —CH 2 —; a single bond; —S(O) 2 —; —C(O)—; or —CH(CH 3 )—.

22. A compound according to claim 1 , wherein each R 3 is halo or —(C 1 C 3 alkyl).

23. A compound according to claim 1 , wherein

R 5 is halo, cyano, —(C 1 -C 3 haloalkyl), or NO 2;

Q is —CH 2 —; a single bond; —S(O) 2 —; —C(O)—; or —CH(CH 3 )—;

x is 0;

w is 0;

R 1 is H;

v is 0;

G is —CH 2 —; a single bond; —S(O) 2 —; —C(O)—; or —CH(CH 3 )—; and

R 17 is phenyl or pyridyl, optionally substituted with one or two substituents selected from halo, cyano, —(C 1 -C 3 fluoroalkyl), and NO 2 .

24. A compound according to claim 1 , wherein G is —CH 2 —, a single bond, —S(O) 2 —, —C(O)— or —CH(CH 3 )—; and Q is —CH 2 —, a single bond, —C(O)—, —S(O) 2 — or —CH(CH 3 )—.

Assignments (2)
SECURITY INTEREST Recorded Aug 25, 2022
From: RIGEL PHARMACEUTICALS, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 061327/0712 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2010
From: DARWISH, IHAB S.; HONG, HUI; SINGH, RAJINDER; XU, XIANG
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 024392/0254 →